Which parts of TB-500 legal status affect patient care?

What did pharmacy advisers decide in July 2026?

TB-500 legal status was discussed by FDA's pharmacy advisers in July 2026. Their July 23-24, 2026 agenda named TB-500 free base, without a paired acid, and TB-500 acetate, paired with part of an acid found in vinegar ^[14]. These are distinct chemical forms, so a pharmacy needs an answer about the particular form being prepared. That pairing is called a salt, distinct from table salt, and both forms needed review for section 503A's permitted-ingredient list.

The agenda also named BPC-157, KPV, and MOTs-C, other laboratory-made substances ^[14]. Discussion of those substances cannot answer whether a pharmacy may prepare the substance discussed here. The staff at FDA opposed placing the proposed ingredients on the permitted list. By September 2026, FDA hadn't published the advisers' votes, leaving no final answer from the meeting.

The advisers' discussion didn't itself grant permission for pharmacy use ^[14][15]. FDA must make a rule to add an ingredient to the final 503A list ^[15]. No clear FDA statement confirms a change to pharmacy rules in early-2026 or departure from the safety-risk group in April-2026 ^[15]. Those unconfirmed claims cannot show permission for your pharmacy to use the ingredient ^[15].

Why isn't the changed FDA listing approval for TB-500?

TB-500 has no FDA approval as a medicine to treat people. FDA's page dated April 22, 2026 shows a withdrawn pharmacy request outside Category 2. That group held proposed ingredients raising serious safety concerns, including the fragment of thymosin beta-4 called TB-500. The agency gives no withdrawal date; the page date tells when the information was current.

FDA's September 29, 2023 update had placed the ingredient in Category 2 for section 503A pharmacy preparation ^[14]. FDA feared the substance could make the immune system, which fights germs, react against an injection. Important safety information was missing, without a particular patient illness identified in the entry. The safety entry concerned TB-500, the small copy from thymosin beta-4, rather than drug approval ^[14].

Under Category 2, pharmacies using those ingredients faced possible FDA action because of the safety concerns ^[15]. That earlier Category 2 policy differed from Category 1: FDA generally held off action during review, without granting drug approval. A pharmacy using a Category 2 ingredient had no such assurance. For your prescription, the earlier policy therefore didn't establish that the ingredient could lawfully be used.

On January 7, 2025, FDA stopped putting new ingredient requests into these numbered groups ^[15]. Ingredients already in Category 2 still lacked protection from FDA action, even when their requests were revised. For this former Category 2 ingredient, the group seeking pharmacy permission instead withdrew its request. Under section 503A, FDA has left pharmacy permission unanswered following withdrawal ^[14][15].

What must a pharmacy check before preparing a patient's medicine?

A pharmacy making medicine for a particular patient is providing a service called compounding. Section 503A covers licensed pharmacies and doctors making those individual preparations. Section 503B applies to registered facilities whose larger batches undergo FDA quality checks and inspections ^[15]. The ingredient must meet one of the law's conditions; that requirement applies even with your prescription ^[15].

One condition is an official written standard describing the ingredient and tests for its quality. Another is that an FDA-approved drug already contains that same ingredient. The third is an entry on FDA's permitted-ingredient list for the kind of preparation being made. These conditions concern the ingredient itself, before the pharmacy prepares medicine for you.

A licensed prescriber, someone allowed to write prescriptions, first assesses the patient during an office visit or video call ^[16]. If a medicine is suitable and lawful, the prescriber writes an individual prescription. A 503A pharmacy makes that preparation; a 503B facility may supply larger batches or medicine for office use. A video visit doesn't change which ingredients the pharmacy law permits ^[16].

For TB-500, the group that asked FDA to permit pharmacy use withdrew its request ^[16]. FDA still displays its safety concerns alongside that withdrawn request. TB-500 now appears outside Category 2, without a clear FDA answer permitting section 503A preparation ^[14][16]. Withdrawal of the TB-500 request doesn't show approval, safety, or permission to prepare treatment for you.

Lawful care needs both a suitable prescription and an ingredient the pharmacy may use. A licensed professional has to assess your health and the rules applying to the proposed medicine. No particular pharmacy or clinic is identified here, and no treatment instructions are offered. These general rules cannot settle medical or legal questions about your own prescription.

Does research use settle treatment or sports permission?

Sports following the World Anti-Doping Agency's rules ban TB-500 and thymosin beta-4 during competitions and between events ^[12]. Tests can find the substances in human samples and in samples taken from horses. TB-500 use in racehorses also prompted development of detection tests ^[12]. Detecting use doesn't show that either substance is safe or helpful for treatment.

TB-500 has no approval as a finished human medicine, while the section 503A pharmacy question remains unanswered ^[15]. Permission for a pharmacy ingredient is a separate decision from approval of a finished drug. Some countries apply prescription-medicine rules to the substance, which doesn't settle the rules here. Your prescription needs an answer under the law applying to that particular preparation.

Researchers and animal-care workers use TB-500, without that use establishing approval for treating human illness. Its section 503A request was withdrawn, leaving the ingredient outside Category 2 ^[12][14]. The July 2026 discussion supplied no published final answer permitting pharmacy use. The sports ban remains separate from that unresolved pharmacy question and the lack of drug approval.

What does lack of TB-500 drug approval mean for a patient?

FDA hasn't approved a TB-500 medicine, although the substance is used in research and animal-care work ^[12]. FDA put the ingredient in section 503A's Category 2 safety-risk group on September 29, 2023 ^[14]. The agency's page dated April 22, 2026 shows TB-500 outside Category 2 after withdrawal of the request. Neither that withdrawal nor research use settles pharmacy permission; the sports ban still applies where those rules govern.

Can a prescription alone permit pharmacy preparation of TB-500?

A licensed prescriber must assess your health and write an appropriate prescription ^[16]. A section 503A pharmacy or section 503B facility also needs permission to use the ingredient. FDA still displays safety concerns for TB-500 and hasn't explained pharmacy permission after the request's withdrawal ^[14][16]. No particular prescriber or pharmacy is identified here to settle your case.

Why did advisers review two TB-500 forms under section 503A?

FDA placed the thymosin beta-4 fragment called TB-500 in 503A Category 2 on September 29, 2023 because of safety concerns ^[14]. The July 23-24, 2026 agenda for the 503A list named TB-500 free base, without paired acid, and TB-500 acetate, paired with part of an acid found in vinegar. Both forms needed their own answer about permission for pharmacy preparation. The paired form is a chemical salt, distinct from table salt; FDA staff opposed both forms and no advisers' votes were published ^[14].